Bayer breakfast symposium "Update on hypogonadism therapy"

Description

Obesity, insulin resistance and type 2 diabetes are highly prevalent risk factors for the development of functional hypogonadotropic hypogonadism (commonly referred to as age-related testosterone deficiency).

Marija Pfeifer presents the results from a 2-year randomized placebo-controlled trial - “The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes” – which randomized 55 obese type 2 diabetic patients to treatment with testosterone undecanoate or placebo injections for 2 years.1

Results showed significant improvements in several metabolic parameters:

  • Reduced insulin resistance (HOMA-IR)
  • Reduced insulin, fasting blood glucose and HbA1c levels
  • Increased flow-mediated dilatation (a measure of endothelial function)
  • Reduced carotid intima media thickness (a measure of atherosclerosis)

Testosterone therapy also reduced the degree of liver fat content and improved the Aging Males' Symptoms scale (AMS) sexual score.


 

Speakers

Prof. Dr. med. Marija Pfeifer

Prof. Dr. Med. Marija Pfeifer
Medical Faculty
University of Ljubljana,
Slovenia

References

  • Groti K, Zuran I, Antonic B, Forsnaric L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. The aging male : the official journal of the International Society for the Study of the Aging Male. 2018;21(3):158-169. Return to content